Prescribing depot buprenorphine in primary care

Speciality Classification
General Practice ( GP ) / Family Medicine
Location
Online
Delivery
Online

On-demand recorded 1 Apr 2020

From 3 April 2020, Buvidal® - one of the two depot buprenorphine formulations available for the treatment of opioid dependency - will be able to be prescribed in the primary care setting.

This webinar will help GPs:

  • Identify patients suitable for depot buprenorphine
  • Implement depot buprenorphine as an OAT for opioid dependency, specifically in relation to prescribing, induction, dose alterations & reduction off the drug
  • Incorporate treatment with depot buprenorphine into your practice
  • Comply with regulatory requirements of prescribing and storing of depot buprenorphine
Learning outcomes
  • Identify patients suitable for depot buprenorphine
  • Implement depot buprenorphine as an OAT for opioid dependency, specifically in relation to prescribing, induction, dose alterations & reduction off the drug
  • Incorporate treatment with depot buprenorphine into your practice
  • Comply with regulatory requirements of prescribing and storing of depot buprenorphine
  • Presenters

    Dr Hester Wilson
    (FRACGP, FAChAM)

    Chair of Specific Interest Addiction Medicine Network

    Prof. Nicholas Lintzeris
    BMedSc, MBBS, PhD, FAChAM

    Director,Drug and Alcohol Services, SESLHD, University of Sydney

    Kim Nolan
    Principal Pharmaceutical Officer, NSW Ministry of Health

    Type
    Webinar
    Delivery
    Online
    Title
    Prescribing depot buprenorphine in primary care
    Speciality Classification
    General Practice ( GP ) / Family Medicine
    Interest Areas / Topics Covered
    Addiction Medicine
    Location
    ONLINE
    Provider Type
    Non Profit Organisation
    HealthcareLink